Simona Mastroeni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Simona Mastroeni has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Fortes
Department of Epidemiology, Istituto Dermopatico dell'Immacolata, Rome, Italy
6 shared publications - Damiano Abeni
Clinical Epidemiology Unit, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, 00167 Rome, Italy
4 shared publications - Francesca Sampogna
Clinical Epidemiology Unit, Istituto Dermopatico Dell’Immacolata IDI-IRCCS, Rome, Italy
4 shared publications - Francesca Passarelli
Histopathology Unit, Istituto Dermopatico dell'Immacolata-IRCCS, Rome, Italy
3 shared publications - Luca Fania
Skin Cancer Center, Istituto Dermopatico dell’Immacolata-IRCCS, 00167 Rome, Italy
3 shared publications - Anna Dattolo
Laboratory of Experimental Immunology, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, 00167 Rome, Italy
2 shared publications
Latest Publications
- Open Access
Immune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell Analysis
Background/Objectives: BRAF and/or MEK inhibitors are widely used for patients with BRAF-mutated melanoma, but no biomarkers of response or resistance are currently available. Besides adverse events in different organs, target therapy with BRAF and/or MEK inhibitors may induce the onset of immune-related adverse events (irAEs) that have been considered as possible biomarkers of good prognosis in patients with melanoma. Methods: To investigate this aspect, we analyzed the occurrence of irAEs in a cohort of 158 patients treated with BRAF and MEK inhibitors. We also analyzed by flow cytometry the subsets of circulating immune cells in the patients who developed irAEs and matched controls. Results: We found that irAEs occurred in 3 out of 101 patients (3%) who experienced adverse events. These three patients did not exhibit any specific clinical features or circulating immune cell subtypes that could be associated with a positive response to treatment. However, the onset of toxicity in the entire patient cohort was associated with longer progression-free survival. Notably, the frequency of circulating follicular helper T cells increased in all examined patients during the first two months of treatment. Conclusions: The small sample size prevents us from determining whether irAEs are effectively caused by BRAF/MEK inhibitors or if they are a random event. Additionally, we cannot conclude whether irAEs are related to a better outcome. Nevertheless, we note that BRAF/MEK inhibition may alter the composition of circulating immune cells in melanoma patients. This aspect should be investigated further before proposing combinations of target therapies and immunotherapies.
Open AccessImmune-Related Adverse Events in Patients with Melanoma Treated with B-RAF/MEK Target Therapy: Occurrence and Circulating Immune Cell Analysis
Background/Objectives: BRAF and/or MEK inhibitors are widely used for patients with BRAF-mutated melanoma, but no biomarkers of response or resistance are currently available. Besides adverse events in different organs, target therapy with BRAF and/or MEK inhibitors may induce the onset of immune-related adverse events (irAEs) that have been considered as possible biomarkers of good prognosis in patients with melanoma. Methods: To investigate this aspect, we analyzed the occurrence of irAEs in a cohort of 158 patients treated with BRAF and MEK inhibitors. We also analyzed by flow cytometry the subsets of circulating immune cells in the patients who developed irAEs and matched controls. Results: We found that irAEs occurred in 3 out of 101 patients (3%) who experienced adverse events. These three patients did not exhibit any specific clinical features or circulating immune cell subtypes that could be associated with a positive response to treatment. However, the onset of toxicity in the entire patient cohort was associated with longer progression-free survival. Notably, the frequency of circulating follicular helper T cells increased in all examined patients during the first two months of treatment. Conclusions: The small sample size prevents us from determining whether irAEs are effectively caused by BRAF/MEK inhibitors or if they are a random event. Additionally, we cannot conclude whether irAEs are related to a better outcome. Nevertheless, we note that BRAF/MEK inhibition may alter the composition of circulating immune cells in melanoma patients. This aspect should be investigated further before proposing combinations of target therapies and immunotherapies.
- Open Access
Genetic Variants and Lifestyle Factors in Androgenetic Alopecia Patients: A Case–Control Study of Single Nucleotide Polymorphisms and Their Contribution to Baldness Risk
Single nucleotide polymorphisms (SNPs) found to be associated with Androgenetic Alopecia (AGA) to date, are characterized by an apparent reduced penetrance into the phenotype suggesting a role of other factors in the etiology of AGA. Objective: We conducted a study to investigate the role of specific allelic variants in AGA controlling for nutritional and lifestyle factors. Methods: Individual patterns of SNPs present in the baldness susceptibility locus at 20p11 (rs1160312 and rs6113491) or close to the androgen receptor (AR) gene in chromosome X (rs1041668) were investigated in 212 male subjects. Information on socio-demographic characteristics, medical history, smoking, and diet was also collected. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Results: After controlling for age, diet, BMI, family history of AGA, and smoking, an increased risk of AGA was found for subjects with [A] alleles for both rs1160312 (OR: 2.97; 95% CI: 1.34–6.62) and rs6113491 (OR: 2.99; 95% CI: 1.37–6.52), and for subjects with the TT genotype for rs1041668 (OR: 4.47; 95% CI: 1.60–12.5). Multivariate logistic regression indicates that diet, familiarity, and BMI, but not smoking, remain statistically significant despite the different SNP genotypes. Conclusions: To our knowledge, this is the first indication that the rs1160312, rs6113491, and rs1041668 polymorphisms are independent risk factors for AGA that can be modulated by diet.
Open AccessGenetic Variants and Lifestyle Factors in Androgenetic Alopecia Patients: A Case–Control Study of Single Nucleotide Polymorphisms and Their Contribution to Baldness Risk
Single nucleotide polymorphisms (SNPs) found to be associated with Androgenetic Alopecia (AGA) to date, are characterized by an apparent reduced penetrance into the phenotype suggesting a role of other factors in the etiology of AGA. Objective: We conducted a study to investigate the role of specific allelic variants in AGA controlling for nutritional and lifestyle factors. Methods: Individual patterns of SNPs present in the baldness susceptibility locus at 20p11 (rs1160312 and rs6113491) or close to the androgen receptor (AR) gene in chromosome X (rs1041668) were investigated in 212 male subjects. Information on socio-demographic characteristics, medical history, smoking, and diet was also collected. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Results: After controlling for age, diet, BMI, family history of AGA, and smoking, an increased risk of AGA was found for subjects with [A] alleles for both rs1160312 (OR: 2.97; 95% CI: 1.34–6.62) and rs6113491 (OR: 2.99; 95% CI: 1.37–6.52), and for subjects with the TT genotype for rs1041668 (OR: 4.47; 95% CI: 1.60–12.5). Multivariate logistic regression indicates that diet, familiarity, and BMI, but not smoking, remain statistically significant despite the different SNP genotypes. Conclusions: To our knowledge, this is the first indication that the rs1160312, rs6113491, and rs1041668 polymorphisms are independent risk factors for AGA that can be modulated by diet.
- Open Access
- 16 October 2024
- Published by PAGEPress Publications in Dermatology Reports
- Vol. 17 (2)
Health-related quality of life and clinical characteristics of hidradenitis suppurativa in a pediatric population
Hidradenitis suppurativa (HS) is a chronic, skin-immunemediated inflammatory disease (sIMID), with a high impact on quality of life (QoL). Data on clinical management, comorbidities, psychosocial burden, and psychiatric disorders in pediatric patients with HS are scarce. The aim of our study was to compare clinical characteristics and patient-reported outcome measures (PROMs) for health-related quality of life (HRQoL) in adult and pediatric patients with HS. Data were collected on 601 patients with HS, 60 of whom (10.0%) were pediatric. The psychological and HRQoL impact was generally higher in adults than children, but it was also noteworthy in pediatric patients. Early diagnosis and interventions based on education for the patients and their families and psychological support are the key to optimal disease management and adherence. Our study underlines the need for screening for HS-associated psychiatric disorders and for using age-specific tools to evaluate HRQoL. A multidisciplinary approach involving several specialists is needed, as well as liaison with primary care specialists to improve care and management of comorbidities and psychological issues in patients with HS.
- 16 October 2024
- Published by PAGEPress Publications in Dermatology Reports
- Vol. 17 (2)
Open AccessHealth-related quality of life and clinical characteristics of hidradenitis suppurativa in a pediatric population
Hidradenitis suppurativa (HS) is a chronic, skin-immunemediated inflammatory disease (sIMID), with a high impact on quality of life (QoL). Data on clinical management, comorbidities, psychosocial burden, and psychiatric disorders in pediatric patients with HS are scarce. The aim of our study was to compare clinical characteristics and patient-reported outcome measures (PROMs) for health-related quality of life (HRQoL) in adult and pediatric patients with HS. Data were collected on 601 patients with HS, 60 of whom (10.0%) were pediatric. The psychological and HRQoL impact was generally higher in adults than children, but it was also noteworthy in pediatric patients. Early diagnosis and interventions based on education for the patients and their families and psychological support are the key to optimal disease management and adherence. Our study underlines the need for screening for HS-associated psychiatric disorders and for using age-specific tools to evaluate HRQoL. A multidisciplinary approach involving several specialists is needed, as well as liaison with primary care specialists to improve care and management of comorbidities and psychological issues in patients with HS.
- Open Access
- 24 May 2024
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 67 (1) , 1-25
Perinatal mental health care in the Italian mental health departments: a national survey
Background: Evidence on the negative outcomes of untreated mental disorders during pregnancy and in the first year after childbirth on women’s and children’s health has stimulated interest in how to develop and sustain high-quality mental health care during the perinatal period. In Italy, there is a lack of knowledge about how mental health services support women with perinatal mental disorders (PMDs). This study aims to describe the adoption of good practices for the prevention and care of PMDs by the Italian mental health departments (MHDs). Methods: This is a nationwide cross-sectional survey conducted online using LimeSurvey. Starting from the Ministry of Health Registry’s 127 MHDs were invited to participate between February and March, 2023. Characteristics of the participating MHDs were reported as descriptive statistics. Results: One hundred nineteen MHDs participated, with a response rate of 93.7%. Regarding the prevention of PMDs, 69 (58.0%) MHDs offer preconception counseling, whereas only 6 (5.0%) have information material for this purpose. Written integrated care pathways for PMDs are not available in 94 (79.7%) MHDs. A reference professional for psychopharmacological treatment during pregnancy or breastfeeding is available in 55 (46.2%) MHDs, while a specific treatment plan for women with PMDs is adopted by 27 (22.7%) MHDs. Thirty-four (28.6%) MHDs have established an outpatient clinic for PMDs, whereas there are no inpatient psychiatric facilities designed for mothers and infants (mother-baby units). Conclusions: There is a need to improve the care of women with PMDs in Italy. The provision of pre-conception counseling, integrated care pathways, and specialist skills and facilities for PMDs should be prioritized.
- 24 May 2024
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 67 (1) , 1-25
Open AccessPerinatal mental health care in the Italian mental health departments: a national survey
Background: Evidence on the negative outcomes of untreated mental disorders during pregnancy and in the first year after childbirth on women’s and children’s health has stimulated interest in how to develop and sustain high-quality mental health care during the perinatal period. In Italy, there is a lack of knowledge about how mental health services support women with perinatal mental disorders (PMDs). This study aims to describe the adoption of good practices for the prevention and care of PMDs by the Italian mental health departments (MHDs). Methods: This is a nationwide cross-sectional survey conducted online using LimeSurvey. Starting from the Ministry of Health Registry’s 127 MHDs were invited to participate between February and March, 2023. Characteristics of the participating MHDs were reported as descriptive statistics. Results: One hundred nineteen MHDs participated, with a response rate of 93.7%. Regarding the prevention of PMDs, 69 (58.0%) MHDs offer preconception counseling, whereas only 6 (5.0%) have information material for this purpose. Written integrated care pathways for PMDs are not available in 94 (79.7%) MHDs. A reference professional for psychopharmacological treatment during pregnancy or breastfeeding is available in 55 (46.2%) MHDs, while a specific treatment plan for women with PMDs is adopted by 27 (22.7%) MHDs. Thirty-four (28.6%) MHDs have established an outpatient clinic for PMDs, whereas there are no inpatient psychiatric facilities designed for mothers and infants (mother-baby units). Conclusions: There is a need to improve the care of women with PMDs in Italy. The provision of pre-conception counseling, integrated care pathways, and specialist skills and facilities for PMDs should be prioritized.
- 10 March 2023
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (7) , 2023-2026
Comparison of self-reported and measured height and weight in patients with psoriasis
- 10 March 2023
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (7) , 2023-2026
Comparison of self-reported and measured height and weight in patients with psoriasis
- Open Access
- 27 January 2023
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 103, adv00856
Similar Levels of Disease Severity Correspond to a Greater Burden of Illness in Women Compared with Men with Hidradenitis Suppurativa
Is missing (Short communication)
- 27 January 2023
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 103, adv00856
Open AccessSimilar Levels of Disease Severity Correspond to a Greater Burden of Illness in Women Compared with Men with Hidradenitis Suppurativa
Is missing (Short communication)
- 23 August 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (3) , 473-479
Quality of life in patients with early- and late-onset hidradenitis suppurativa
Hidradenitis suppurativa (HS) usually has an early onset, however, also onset in the mid-40 s may occur. Recently, the threshold of 28 years to distinguish patients with early and late onset has been proposed. The objective of our study was to compare the quality of life (QoL) and psychological distress in early- and late-onset HS patients. In this cross-sectional, observational study, consecutive patients diagnosed with HS aged ≥ 16 years were recruited. Dermatology-specific QoL was evaluated using the Skindex-17 questionnaire, and psychological distress using the 12-item General Health Questionnaire (GHQ-12). Patients were categorized into “early onset” (< 28 years) and “late onset” (≥ 28 years). Data were collected on 467 patients. Mean age at diagnosis was 21.6 years, with 22.0% of patients presenting with late disease onset. Patients with late onset reported worse psychosocial QoL and higher psychological distress compared to early onset. No differences between the two groups were observed for clinical severity. In the final multivariate model lower diagnostic delay, higher number of fistulae, higher BMI, ex-smoker, no localization on axillae, no localization on mammary region, presence of psoriasis, and higher scores on the psychosocial scale of Skindex-17 were statistically significantly associated with late onset. In conclusion, the psychosocial impact of HS is higher in patients with late onset compared to those with early onset. Differences between these two groups should be further investigated.
- 23 August 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (3) , 473-479
Quality of life in patients with early- and late-onset hidradenitis suppurativa
Hidradenitis suppurativa (HS) usually has an early onset, however, also onset in the mid-40 s may occur. Recently, the threshold of 28 years to distinguish patients with early and late onset has been proposed. The objective of our study was to compare the quality of life (QoL) and psychological distress in early- and late-onset HS patients. In this cross-sectional, observational study, consecutive patients diagnosed with HS aged ≥ 16 years were recruited. Dermatology-specific QoL was evaluated using the Skindex-17 questionnaire, and psychological distress using the 12-item General Health Questionnaire (GHQ-12). Patients were categorized into “early onset” (< 28 years) and “late onset” (≥ 28 years). Data were collected on 467 patients. Mean age at diagnosis was 21.6 years, with 22.0% of patients presenting with late disease onset. Patients with late onset reported worse psychosocial QoL and higher psychological distress compared to early onset. No differences between the two groups were observed for clinical severity. In the final multivariate model lower diagnostic delay, higher number of fistulae, higher BMI, ex-smoker, no localization on axillae, no localization on mammary region, presence of psoriasis, and higher scores on the psychosocial scale of Skindex-17 were statistically significantly associated with late onset. In conclusion, the psychosocial impact of HS is higher in patients with late onset compared to those with early onset. Differences between these two groups should be further investigated.
- Open Access
- 1 June 2021
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 84 (6) , 1762-1764
The chronic use of multiple photosensitizing drugs is associated with Breslow thickness in female melanoma patients: A bicentric retrospective study
- 1 June 2021
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 84 (6) , 1762-1764
Open AccessThe chronic use of multiple photosensitizing drugs is associated with Breslow thickness in female melanoma patients: A bicentric retrospective study
- Open Access
- 1 July 2014
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 142 (1) , 121-132
High Expression of the Mismatch Repair Protein MSH6 Is Associated With Poor Patient Survival in Melanoma
Objectives: The outcome of patients with primary melanoma (PM) cannot be completely explained based on currently adopted clinical-histopathologic criteria. In this study, we evaluated the potential prognostic value of mismatch repair protein expression in PMs.Methods: We examined the immunohistochemical staining of mismatch repair proteins in 18 benign nevi and 101 stage I to III PMs and investigated their association with tumor clinicopathologic variables and melanoma mortality.Results: Expression of MSH2, MLH1, and PMS2 was high in benign nevi and reduced in a subset of PMs. Conversely, MSH6 expression was absent or extremely low in benign nevi and increased in a subset of PMs. In the multivariate analysis, including sex, age, Breslow thickness, and ulceration, high MSH6 expression in PMs (ie, immunostaining in >20% of tumor cells) was significantly associated with an increased risk of melanoma mortality (relative risk, 3.76; 95% confidence interval, 1.12–12.70).Conclusions: MSH6 protein expression can be a valuable marker to improve prognosis assessment in PMs.
- 1 July 2014
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 142 (1) , 121-132
Open AccessHigh Expression of the Mismatch Repair Protein MSH6 Is Associated With Poor Patient Survival in Melanoma
Objectives: The outcome of patients with primary melanoma (PM) cannot be completely explained based on currently adopted clinical-histopathologic criteria. In this study, we evaluated the potential prognostic value of mismatch repair protein expression in PMs.Methods: We examined the immunohistochemical staining of mismatch repair proteins in 18 benign nevi and 101 stage I to III PMs and investigated their association with tumor clinicopathologic variables and melanoma mortality.Results: Expression of MSH2, MLH1, and PMS2 was high in benign nevi and reduced in a subset of PMs. Conversely, MSH6 expression was absent or extremely low in benign nevi and increased in a subset of PMs. In the multivariate analysis, including sex, age, Breslow thickness, and ulceration, high MSH6 expression in PMs (ie, immunostaining in >20% of tumor cells) was significantly associated with an increased risk of melanoma mortality (relative risk, 3.76; 95% confidence interval, 1.12–12.70).Conclusions: MSH6 protein expression can be a valuable marker to improve prognosis assessment in PMs.
- 16 July 2012
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 39 (9) , 826-834
Expression of vascular endothelial growth factor‐C in primary cutaneous melanoma predicts sentinel lymph node positivity
Background: Vascular endothelial growth factor‐C (VEGF‐C), a lymphatic vessel growth factor, has been involved in the formation of lymph nodal metastases in different tumor types. Early evidences indicate that VEGF‐C expression in human primary melanoma could be predictive of lymph nodal metastases, whereas the role of lymphangiogenesis is still controversial.Methods: By immunohistochemical analysis, we investigated VEGF‐C or CC chemokine receptor 7 expression, together with the lymphatic and blood vessel network, in 36 patients with primary skin melanomas and metastases at the sentinel lymph node biopsy (SLN‐positive), and 26 melanoma patients with negative SLN biopsy (SLN‐negative).Results: We found that VEGF‐C expression in primary melanoma specimens was significantly associated with SLN‐positive (p < 0.001), particularly in thin melanomas. An association between augmented peritumoral lymphatic vessel area and SLN‐positive (p < 0.02) was also seen. Conversely, no association between either expression of the CC chemokine receptor 7 in the primary tumor, or intratumoral lymphatic vessel or peritumoral and intratumoral blood vessel area, and SLN‐positive was found.Conclusions: Our results, taking into account the expression of either VEGF‐C or related histopathological markers, indicated the possibility to use VEGF‐C immunohistochemistry as a marker of metastatic progression, especially in thin cutaneous melanomas.
- 16 July 2012
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 39 (9) , 826-834
Expression of vascular endothelial growth factor‐C in primary cutaneous melanoma predicts sentinel lymph node positivity
Background: Vascular endothelial growth factor‐C (VEGF‐C), a lymphatic vessel growth factor, has been involved in the formation of lymph nodal metastases in different tumor types. Early evidences indicate that VEGF‐C expression in human primary melanoma could be predictive of lymph nodal metastases, whereas the role of lymphangiogenesis is still controversial.Methods: By immunohistochemical analysis, we investigated VEGF‐C or CC chemokine receptor 7 expression, together with the lymphatic and blood vessel network, in 36 patients with primary skin melanomas and metastases at the sentinel lymph node biopsy (SLN‐positive), and 26 melanoma patients with negative SLN biopsy (SLN‐negative).Results: We found that VEGF‐C expression in primary melanoma specimens was significantly associated with SLN‐positive (p < 0.001), particularly in thin melanomas. An association between augmented peritumoral lymphatic vessel area and SLN‐positive (p < 0.02) was also seen. Conversely, no association between either expression of the CC chemokine receptor 7 in the primary tumor, or intratumoral lymphatic vessel or peritumoral and intratumoral blood vessel area, and SLN‐positive was found.Conclusions: Our results, taking into account the expression of either VEGF‐C or related histopathological markers, indicated the possibility to use VEGF‐C immunohistochemistry as a marker of metastatic progression, especially in thin cutaneous melanomas.